FOR IMMEDIATE RELEASE
Media Contact:
Katrina Norfleet
+1.240.221.2924
knorfleet@arvo.org
Posted: 5/10/2017
Predatory bacteria kills multi-drug resistant bacteria on eyes
 

Baltimore, Md. – Scientists have developed a new method to clear antibiotic resistant bacteria from the surface of the eye — introducing a new strain of bacteria that preys on other microorganisms. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.

Experiments on rabbit eyes compared the ability of predatory bacteria and vancomycin, an antibiotic, to treat an infection of multi-drug resistant P. aeruginosa. The predatory bacteria proved superior to vancomycin in terms of time-to-bacterial clearing, wound healing inhibition and toxicity. The researchers noted a remarkable inhibition of wound healing by vancomycin, whereas predatory bacteria did not alter wound healing.

The increasing spread of antibiotic resistant microorganisms is a global health problem. Multi-drug resistant P. aeruginosa, which is spread by contact with a contaminated surface or water, can cause severe illness and death in people in the hospital and/or with weakened immune systems. It can cause eye infections in healthy people using extended-wear contact lenses. Vancomycin is used to treat MRSA infections.

Abstract title: Evaluation of predatory bacteria on corneal wound healing, ocular safety, and clearance of fluoroquinolone resistant Pseudomonas aeruginosa from the ocular surface a

Presentation start/end time: Wednesday, May 10, 2017, 11:15 – 11:30am 

Location: Room 310 

Abstract number: 4291

# # #


The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.

All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.

Advertisement
Phoenix research labs